Bristol-Myers Squibb Company (BMY.US) rises in pre-market trading! Two experimental drugs report positive Phase III clinical results, accelerating pipeline diversification.

Bristol-Myers Squibb Company (BMY.US) reported success in Phase III clinical studies for two experimental drugsone for a rare endocrine cancer and one for a fatal lung diseasegiving momentum to the pharmaceutical company's new product pipeline. Boosted by the news, as of press time, Bristol-Myers Squibb Company rose nearly 4% in Monday's U.S. pre-market trading. Bristol-Myers Squibb Company said that the Phase III ALPFT-IPF trial of its LPA1 antagonist Admilparant for the treatment of idiopathic pulmonary fibrosis (IPF) met the primary endpoint of FVC. The trial is part of the third and final phase of clinical testing required before a new drug can be approved. Idiopathic pulmonary fibrosis is a chronic disease that causes scarring in the lungs and makes it difficult for oxygen to enter the bloodstream. It is reported that patients with idiopathic pulmonary fibrosis experienced significant improvement in their breathing after taking a lower-dose version of Admilparant. Meanwhile, Bristol-Myers Squibb Company said that an interim analysis of the Phase III ACTION-1 trial of its SSTR2-targeted radiopharmaceutical RYZ101 in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) met the primary endpoint of PFS. The Phase III trial targeted patients treated with Lu-177-based therapy. Gastroenteropancreatic neuroendocrine tumors are a rare cancer that originates in endocrine cells of the gastrointestinal tract or pancreas. The analysis found that the company's RYZ101 was able to significantly slow disease progression. Bristol-Myers Squibb Company is making pipeline diversification a strategic priority to counter the impact of patent expirations on multiple key products. The company aims to launch more than 10 new drugs by 2030, building a diversified product portfolio spanning multiple therapeutic areas. At a conference earlier this year, Bristol-Myers Squibb Company highlighted six pipeline programs with multi-billion-dollar sales potential, including the antipsychotic Cobenfy (xanomeline + trospium chloride), the anticoagulant Milvexian, the pulmonary fibrosis drug Admilparant, the PD-L1/VEGF-A bispecific antibody Pumitamig, and two molecular glue drugs, Iberdomide and Mezigdomide. These programs cover multiple areas including neuroscience, cardiovascular, immunology, and oncology. Bristol-Myers Squibb Company CEO Chris Boerner revealed that the company has completed $30 billion worth of deals over the past two years, five of which were reached in 2025, and will continue to pursue better performance growth through strategic transactions in the future.